Patents by Inventor CHRISTINE KLAUS

CHRISTINE KLAUS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20240041895
    Abstract: The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.
    Type: Application
    Filed: March 23, 2023
    Publication date: February 8, 2024
    Inventors: Christine KLAUS, Maria Alejandra RAIMONDI
  • COMBINATION THERAPIES WITH EHMT2 INHIBITORS
    Publication number: 20230364086
    Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 23, 2023
    Publication date: November 16, 2023
    Inventors: John Emmerson CAMPBELL, Kenneth William DUNCAN, Maria Alejandra RAIMONDI, Christine KLAUS, Elayne PENEBRE
  • Combination therapies with EHMT2 inhibitors
    Patent number: 11672800
    Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 13, 2023
    Assignee: Epizyme, Inc.
    Inventors: John Emmerson Campbell, Kenneth William Duncan, Maria Alejandra Raimondi, Christine Klaus, Elayne Penebre
  • Combination therapy for treating cancer
    Patent number: 11642346
    Abstract: The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: May 9, 2023
    Assignee: Epizyme, Inc.
    Inventors: Christine Klaus, Maria Alejandra Raimondi
  • METHODS OF USING EHMT2 INHIBITORS
    Publication number: 20230087806
    Abstract: The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: September 14, 2021
    Publication date: March 23, 2023
    Inventors: John Emmerson CAMPBELL, Kenneth William DUNCAN, Elayne PENEBRE, Kat COSMOPOULOS, Christine KLAUS
  • 6?-sialyllactose for use in the treatment of hearing loss
    Patent number: 11291675
    Abstract: The present invention relates to 6?-sialyllactose and/or pharmaceutically acceptable salts thereof for use in the treatment of a disease selected from hearing loss and hearing loss—associated tinnitus.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: April 5, 2022
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Harald Neumann, Christine Klaus, Anahita Shahraz
  • ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20210379076
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: May 5, 2021
    Publication date: December 9, 2021
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J. N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
  • Aryl-or heteroaryl-substituted benzene compounds
    Patent number: 11052093
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: July 6, 2021
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20210100810
    Abstract: The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.
    Type: Application
    Filed: March 30, 2018
    Publication date: April 8, 2021
    Inventors: Christine KLAUS, Maria Alejandra RAIMONDI
  • 6'-SIALYLLACTOSE FOR USE IN THE TREATMENT OF HEARING LOSS
    Publication number: 20200289537
    Abstract: The present invention relates to 6?-sialyllactose and/or pharmaceutically acceptable salts thereof for use in the treatment of a disease selected from hearing loss and hearing loss—associated tinnitus.
    Type: Application
    Filed: December 7, 2018
    Publication date: September 17, 2020
    Applicant: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Harald NEUMANN, Christine KLAUS
  • ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20200155562
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: October 22, 2019
    Publication date: May 21, 2020
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J. N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
  • METHODS OF USING EHMT2 INHIBITORS
    Publication number: 20200113901
    Abstract: The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 30, 2018
    Publication date: April 16, 2020
    Inventors: John Emmerson CAMPBELL, Kenneth William DUNCAN, Elayne PENEBRE, Kat COSMOPOULOS, Christine KLAUS
  • COMBINATION THERAPIES WITH EHMT2 INHIBITORS
    Publication number: 20200054635
    Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
    Type: Application
    Filed: April 20, 2018
    Publication date: February 20, 2020
    Inventors: John Emmerson CAMPBELL, Kenneth William DUNCAN, Maria Alejandra RAIMONDI, Christine KLAUS, Elayne PENEBRE
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20200030355
    Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: January 16, 2019
    Publication date: January 30, 2020
    Inventors: Christine KLAUS, Maria Alejandra RAIMONDI, Scott Richard DAIGLE, Roy MacFarlane POLLOCK, Vivek CHOPRA
  • Combination therapy for treating cancer
    Patent number: 10525074
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 7, 2020
    Assignee: Epizyme, Inc.
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott R. Daigle, Roy MacFarlane Pollock
  • Aryl-or heteroaryl-substituted benzene compounds
    Patent number: 10420775
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: September 24, 2019
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20190083521
    Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: August 12, 2015
    Publication date: March 21, 2019
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott Richard Daigle, Roy MacFarlane Pollock
  • Aryl- or heteroaryl-substituted benzene compounds
    Patent number: 10155002
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: December 18, 2018
    Assignee: Epizyme, Inc.
    Inventors: Kevin Wayne Kuntz, Richard Chesworth, Kenneth William Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah Kathleen Knutson, Timothy James Nelson Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20180318309
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: November 17, 2017
    Publication date: November 8, 2018
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J.N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20180028552
    Abstract: The present disclosure relates to a combination of an inhibitor of human histone methyltransferase DOT1L, such as EPZ-5676 or salts thereof, and one or more DNMT inhibitors, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: February 1, 2016
    Publication date: February 1, 2018
    Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott Richard Daigle, Roy MacFarlane Pollock, Vivek Chopra